Name:
ARGX-113-2011: A study to assess the long-term safety and efficacy of subcutaneous efgartigimod in adults with IIM.
Description:
An open-label extension study evaluating the long-term safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with idiopathic inflammatory myopathies who have previously participated in a parent study. The trial allows continued access to treatment and ongoing monitoring of disease control.
Stage:
Ongoing (open-label extension; not recruiting new patients – only enrolling from parent study)
Principal Investigator:
Prof Eamonn Molloy
Sponsor:
ARGENX
Network Partners
